Filgrastim biosimilar - Sandoz

Drug Profile

Filgrastim biosimilar - Sandoz

Alternative Names: EP2006; Filgrastim Hexal (Sandoz); Filgrastim-sndz; Zarxio; Zarzio

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sandoz
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Febrile neutropenia

Most Recent Events

  • 01 Jun 2018 Adverse events data from the phase III PIONEER and observational MONITOR-GCSF trial in Febrile neutropenia presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 17 May 2017 Efficacy and adverse events data from the phase III PIONEER trial in Febrile neutropenia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 26 May 2015 No recent reports of development identified - Phase-III for Febrile neutropenia (Prevention) in Russia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top